Increased leukotriene E4 excretion in systemic mastocytosis

被引:40
作者
Butterfield, Joseph H. [1 ]
机构
[1] Mayo Clin, Div Allerg Dis, Rochester, MN 55905 USA
关键词
Leukotriene E-4; Mast cells; Systemic mastocytosis; URINARY LEUKOTRIENE-E4; NASAL POLYPOSIS; RECEPTOR; DISEASE; 5-LIPOXYGENASE; ASTHMA; MONTELUKAST; INVOLVEMENT; INHIBITION; CHILDREN;
D O I
10.1016/j.prostaglandins.2010.03.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cysteinyl leukotrienes such as LTE4 are produced by mast cells, neutrophils, eosinophils, and macrophages. LTE4 levels have not been reported in systemic mastocytosis, a disorder with a large increase in mast cell numbers. Urinary LTE4 from patients referred for symptoms potentially due to mast cell degranulation or systemic mastocytosis was measured by a commercial cysteinyl leukotriene enzyme immunoassay kit. The diagnosis of systemic mastocytosis was established using current World Health Organization criteria. Compared with a control group of patients with various potential mast cell-related symptoms (e.g., "spells"), patients with systemic mastocytosis had a significant (P=.01) increase in urinary LTE4 excretion, whether expressed as LTE4 ng/g creatinine or as LTE4 ng/24 h. There was a moderate correlation of LTE4 ng/24 h with excretion of N-methyl histamine and serum tryptase but not with urinary 11 beta-prostaglandin F-2 alpha(11 beta-PGF(2 alpha)) excretion. LTE4 excretion is increased in patients with systemic mastocytosis and potentially contributes to clinical symptoms. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:73 / 76
页数:4
相关论文
共 32 条
[1]   ENHANCED EXCRETION OF URINARY LEUKOTRIENE-E(4) IN CORONARY-ARTERY DISEASE AND AFTER CORONARY-ARTERY BYPASS-SURGERY [J].
ALLEN, SP ;
SAMPSON, AP ;
PIPER, PJ ;
CHESTER, AH ;
OHRI, SK ;
YACOUB, MH .
CORONARY ARTERY DISEASE, 1993, 4 (10) :899-904
[2]   Zileuton: clinical implications of 5-Lipoxygenase inhibition in severe airway disease [J].
Berger, W. ;
De Chandt, M. T. M. ;
Cairns, C. B. .
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (04) :663-676
[3]   The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis [J].
Bouchelouche, K ;
Nordling, J ;
Hald, T ;
Bouchelouche, P .
JOURNAL OF UROLOGY, 2001, 166 (05) :1734-1737
[4]   Systemic mastocytosis: Clinical manifestations and differential diagnosis [J].
Butterfield, Joseph H. .
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2006, 26 (03) :487-+
[5]   INCREASED URINARY LEUKOTRIENE EXCRETION IN PATIENTS WITH CARDIAC ISCHEMIA - INVIVO EVIDENCE FOR 5-LIPOXYGENASE ACTIVATION [J].
CARRY, M ;
KORLEY, V ;
WILLERSON, JT ;
WEIGELT, L ;
FORDHUTCHINSON, AW ;
TAGARI, P .
CIRCULATION, 1992, 85 (01) :230-236
[6]   Mast cell mediators in allergic inflammation and mastocytosis [J].
Castells, Mariana .
IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2006, 26 (03) :465-+
[7]   Irritable bowel syndrome helped by montelukast [J].
Fee, WH .
CHEST, 2002, 122 (04) :1497-1497
[8]   ATOPIC CHILDREN WITH CYSTIC-FIBROSIS HAVE INCREASED URINARY LEUKOTRIENE E(4) CONCENTRATIONS AND MORE SEVERE PULMONARY-DISEASE [J].
GREALLY, P ;
COOK, AJ ;
SAMPSON, AP ;
COLEMAN, R ;
CHAMBERS, S ;
PIPER, PJ ;
PRICE, JF .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1994, 93 (01) :100-107
[9]   Characterization of the human cysteinyl leukotriene 2 receptor [J].
Heise, CE ;
O'Dowd, BF ;
Figueroa, DJ ;
Sawyer, N ;
Nguyen, T ;
Im, DS ;
Stocco, R ;
Bellefeuille, JN ;
Abramovitz, M ;
Cheng, R ;
Williams, DL ;
Zeng, ZZ ;
Liu, QY ;
Ma, L ;
Clements, MK ;
Coulombe, N ;
Liu, Y ;
Austin, CP ;
George, SR ;
O'Neill, GP ;
Metters, KM ;
Lynch, KR ;
Evans, JF .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (39) :30531-30536
[10]   Clinical features of asthmatic patients with increased urinary leukotriene E4 excretion (hyperleukotrienuria): Involvement of chronic hyperplastic rhinosinusitis with nasal polyposis [J].
Higashi, N ;
Taniguchi, M ;
Mita, H ;
Kawagishi, Y ;
Ishii, T ;
Higashi, A ;
Osame, M ;
Akiyama, K .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2004, 113 (02) :277-283